Vaccination is considered the most cost effective way to control the pathogens and prevent the diseases both in humans and veterinary field. The vaccines based on virus like particles represent one of the most appealing and cost effective approaches due to the intrinsic immunogenic properties as well as high safety profile. The virus like particles also offers several other advantages against the emerging viruses and these are virus like particles are not live viruses and thus manufacturing process offers a safer environment for the operators.
The modern approach for the development of vaccines is focused on the identification of the molecular entities from different organisms as candidates which can mimic the role of viruses. This approach is certainly safer and produces lesser or no side effects after the vaccination process. Virus-like particles are one of such candidates which have shown most promising results and are currently involved in treating a wide range of diseases.

Virus-like particles are composed of the characteristic building proteins of a virus which mimic the properties of the infectious viruses but lack the viral genome. Therefore, Virus like particles became an extremely impressive and promising vaccine candidates due to the presence of virus like but yet non-infective properties in them. Thus, the viruses like particle based vaccines are potentially safer candidates for developing vaccines. Furthermore, Virus like particles are able to induce both innate and adaptive immune responses in humans. Most of the virus like particle based vaccines are derived from the bacteria E.coli as the bacteria E. coli has many advantages, such as inexpensive culturing, high expression levels and easy large scale production. All these advantages of the bacteria will consequentially serve to the development of more cost effective vaccines.

The virus like particle based vaccines is commercially available in market against the hepatitis B virus and human papillomavirus. The viruses like particle based vaccines against several other viruses are in clinical development. The under trial vaccine candidates itself represents the target antigen and those in which the virus like particle is used to present the foreign antigens to immune system. The progresses have been made in developing virus like particle vaccines against hepatitis C virus, Ebola, Lassa virus, Hantavirus and chikungunya virus. Currently there are 60 virus like particle vaccines in clinical trials and 5 virus like particle vaccines are commercially available in the market.

The major pharmaceutical companies have recognized the promising future of the virus like particle vaccines and are widely supporting the manufacturing and production of such vaccines. Major market players include some of the large scale pharmaceutical companies like GlaxoSmithKline’s and Merck. The development of the cost effective vaccines are hugely supported by the governmental authorities as well as the academia and pharmaceutical companies.

The future of the virus like particle based vaccines is bright owing to the presence of multiple favorable factors and lesser challenges. The low cost and high efficiency combination will contribute as a robust of the virus like particle vaccines market. Such kind of vaccines will be easily accessible to the consumers due to the expanding market size. The future is even more optimistic in the developing countries where low price will be a favorable parameter for increased customers and demands. Overall the future of the virus like particle based vaccine is very bright and may result in replacing the whole human vaccine market by collecting high revenues for the pharmaceutical industry.

ヒトパピローマウイルス（HPV）感染症治療薬の世界市場・治験インサイトDATA7100521 / Kuick Research / 2017年9月 / ...“Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023” report gives comprehensive insight on the ongoing market and clinical development in HPV drug market. Report highlights the trends in the global HPV drug market and gives detailed overview on the HPV drug clinical pipeline by phase, drug class and mode of action. As per report findings, there are 9 HPV drugs commercially available in the market and 78 drugs are in multiple phases of clinical pipeline. Majority of the HPV drugs are in Preclinical phase of development followed by Phase-II clinical trials. In the past decade, there have...

CD抗原癌治療の世界市場動向・治験インサイトKUIK80307 / Kuick Research / 2017年10月 / ...“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries...

癌ヤーヌスキナーゼ阻害剤の世界市場機会・治験インサイトKUIK80308 / Kuick Research / 2017年10月 / ...“Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer janus kinase inhibitor market. As per report findings, janus kinase inhibitors have emerged as one of the new potential candidate and growth frontier for the various stake holders involved in the research and development of cancer drugs and therapies. At present there is only one janus kinase inhibitors based drug commercially available in the market and 27 drugs are in the various clinical development phases. Most of the drugs are in Preclinical...

乳がん検診の米国市場：種類別、シェア、ケース、治験インサイト、医療費償還、競争戦略、市場予測DATA7100536 / DPI Research / 2017年8月10日 / ...United States Breast Cancer Screening Market is expected to reach more than US$ 5.8 Billion by 2022. Long–term Growth Projection: • Mammography grasp the dominant share in the United States Breast Cancer Screening Market • Breast MRI Screening market is likely to reach more than US$ 350 Million by 2022 • Number of mammograpy screening population in United States will increase to more than 50 Million by 2022 Market growth can be attributed to factors such as increasing incidence of breast cancer, increasing awareness related to early breast cancer detection, growing government investments and funding for breast cancer screening, technological...

肺がんワクチンの世界市場・パイプライン見通しKUIK70405 / KuicK Research / 2016年12月 / ...“Global Lung Cancer Vaccine Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are 9 lung cancer vaccines in advance Phase-II clinical trials followed by 8 vaccines Phase-I/II trials. Lung cancer is emerging as one of the most lethal malignancy having high morbidity and...

インフルエンザワクチンのアメリカ市場 2025年DATA8102107 / DPI Research / 2018年10月 / ...United States Influenza Vaccines market is set to touch US$ 3.5 Billion threshold by 2025. “United States Influenza Vaccines Market Report, Analysis and Forecast to 2025” presents an in-depth assessment of the United States influenza vaccines market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for United States influenza vaccines market. The report includes historic data from 2013 to 2017 and forecasts until 2025. The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market...